Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses

Kidney International

Volumn 78, Issue 9, 2010, Pages 934-940

  Struijk, Geertrude H ^a   Minnee, Robert C ^a   Koch, Sven D ^a   Zwinderman, Aeilko H ^a   Van Donselaar Van Der Pant, Karlijn A M I ^a   Idu, Mirza M ^a   Ten Berge, Ineke J M ^a   Bemelman, Frederike J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

everolimus; immunosuppression; mycophenolate; pneumococcus; renal transplantation; vaccination

Indexed keywords

CYCLOSPORIN A; EVEROLIMUS; IMMUNOCYANIN; KEYHOLE LIMPET HEMOCYANIN; MYCOPHENOLIC ACID; PNEUMOCOCCUS VACCINE; PREDNISOLONE; T LYMPHOCYTE ANTIGEN; TETANUS TOXOID; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GRAFT RECIPIENT; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINATION;

EID: 77958110680     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.269     Document Type: Article

References (34)

1. Boggild AK, Sano M, Humar A et al. Travel patterns and risk behavior in solid organ transplant recipients. J Travel Med 2004; 11: 37-43.
2. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741-1751.
3. Vitko S, Margreiter R, Weimar W et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004; 78: 1532-1540. (Pubitemid 39552941)
4. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2004; 4(Suppl 10): 160-163.
5. Harris K, Baggs J, Davis RL et al. Influenza vaccination coverage among adult solid organ transplant recipients at three health maintenance organizations, 1995-2005. Vaccine 2009; 27: 2335-2341.
6. Lanternier F, Henegar C, Mouthon L et al. Low influenza-vaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease. Ann Rheum Dis 2008; 67: 1047.
7. Blumberg EA, Brozena SC, Stutman P et al. Immunogenicity of pneumococcal vaccine in heart transplant recipients. Clin Infect Dis 2001; 32: 307-310.
8. Vilchez RA, McCurry K, Dauber J et al. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2002; 2: 287-291.
9. Cainelli F, Vento S. Infections and solid organ transplant rejection: a cause-and-effect relationship? Lancet Infect Dis 2002; 2: 539-549.
10. Candon S, Thervet E, Lebon P et al. Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients. Am J Transplant 2009; 9: 2346-2354.
11. Ten Berge RJ, Schellekens PT, Surachno S et al. The influence oftherapy with azathioprine and prednisone on the immune system of kidney transplant recipients. Clin Immunol Immunopathol. 1981. 21. 20-32. (Pubitemid 11053436)
12. ten Berge RJ, Schellekens PT, SurachnoS etal. A longitudinal studyon the effects of azathioprine and high doses of prednisone on the immune system of kidney-transplant recipients. Clin Immunol Immunopathol 1982; 24: 33-46.
13. van der Heyden AA, Bloemena E, Out TA et al. The influence of immunosuppressive treatment on immune responsiveness in vivo in kidney transplant recipients. Transplantation 1989; 48: 44-47.
14. Rentenaar RJ, van Diepen FN, Meijer RT et al. Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo. Kidney Int 2002; 62: 319-328.
15. Willcocks LC, Chaudhry AN, Smith JC et al. The effect of sirolimus therapy on vaccine responses in transplant recipients. Am J Transplant 2007; 7: 2006-2011.
16. Webster AC, Lee VW, Chapman Jr et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234-1248.
17. Andres V, Castro C, Campistol JM. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients. Nephrol Dial Transplant 2006; 21(Suppl 3): iii14-iii17.
18. Meier-Kriesche HU, Steffen BJ, Hochberg AM etal. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 2003; 75: 1341-1346.
19. Bemelman FJ, de Maar EF, Press RR et al. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Transplantation 2009; 88: 421-428.
20. Lindemann M, Witzke O, Lutkes P et al. ELISpot assay as a sensitive tool to detect cellular immunity following influenza vaccination in kidney transplant recipients. Clin Immunol 2006; 120: 342-348.
21. Ballet C, Roussey-Kesler G, Aubin JT et al. Humoral and cellular responses to influenza vaccination in human recipients naturally tolerant to a kidney allograft. Am J Transplant 2006; 6: 2796-2801.
22. Smith KG, Isbel NM, Catton MG et al. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant 1998; 13: 160-164.
23. Wasserstrom H, Bussel J, Lim LC et al. Memory B cells and pneumococcal antibody after splenectomy. J Immunol 2008; 181: 3684-3689.
24. Heidt S, Roelen DL, Eijsink C et al. Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. Transplantation 2008; 86: 1292-1300.
25. Araki K, Turner AP, Shaffer VO et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460: 108-112.
26. Coenen JJ, Koenen HJ, van RE et al. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 2006; 107: 1018-1023.
27. Nikolaeva N, Bemelman FJ, Yong SL et al. Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells. Transplantation 2006; 81: 445-454.
28. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009; 9: 324-337.
29. Litjens NH, Huisman M, Hijdra D et al. IL-2 producing memory CD4+ T lymphocytes are closely associated with the generation of IgG-secreting plasma cells. J Immunol 2008; 181: 3665-3673.
30. Hart M, Steel A, Clark SA et al. Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J Immunol 2007; 178: 8212-8220.
31. Gunther M, Stark K, Neuhaus R et al. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. Transplantation 2001; 71: 477-479.
32. Huzly D, Neifer S, Reinke P et al. Routine immunizations in adult renal transplant recipients. Transplantation 1997; 63: 839-845.
33. Korver K, Zeijlemaker WP, Schellekens PT et al. Measurement of primary in vivo IgM-and IgG-antibody response to KLH in humans: implications of pre-immune IgM binding in antigen-specific ELISA. J ImmunolMethods 1984; 74: 241-251.
34. Rodrigo MJ, Miravitlles M, Cruz MJ et al. Characterization of specific immunoglobulin G (IgG) and its subclasses (IgG1 and IgG2) against the 23-valent pneumococcal vaccine in a healthy adult population: proposal for response criteria. Clin Diagn Lab Immunol 1997; 4: 168-172.